Журнал включен в российские и международные библиотечные и реферативные базы данных
РИНЦ (Россия)
Регистрационное агентство DOI (США)
DOI Registration Agency (USA)
Эко-Вектор (Россия)
Eco-Vector (Russia)
Ulrichsweb (Ulrich’s Periodicals Director

Joint damage among the patients with COVID-19 in nurse practice

DOI: https://doi.org/10.29296/25879979-2024-04-10

V.V. Skvortsov, S.E. Matohin, G.S. Akimochkin, A.A. Karchevsky
FSBEI НЕ VolgSMU МОН Russia, Volgograd
е-mail: [email protected]

Rheumatoid pathology of the articular apparatus is a significant social problem due to the high incidence of disability. Cases of the development of arthropathy after SARS-CoV-2 infection have been described.The basis of the pathogenesis of this condition may be the excessive synthesis of pro-inflammatory cytokines (cytokine storm), which is characteristic of the acute course of COVID-19. In patients with a severe form of coronavirus infection, a high concentration of a number of cytokines was observed: IFN-γ, IL-1, IL-6, IL-12, TGFβ. Due to the activation of osteoclasts, resorptive processes in bone tissue were significantly enhanced.Autoimmunization due to cross-reactivity of the virus can also lead to joint damage. Reactive arthritis tends to be acute, occurs in the form of monoarthritis or oligoarthritis. The pathological process develops mainly in the joints of the wrist, ankles and small joints of the distal parts of the arms and legs.

reactive arthritis

  1. Baumhauer J. F. et al. Cytokine-induced osteoclastic bone resorption in charcot arthropathy: an immunohistochemical study. Foot & ankle international. 2006; 27 (10): 797–800.
  2. Carter J. D., Hudson A. P. Reactive arthritis: clinical aspects and medical management //Rheumatic Disease Clinics. 2009; 35 (1): 21–44.
  3. Cincinelli G., Di Taranto R., Orsini F. et al. A case report of monoarthritis in a COVID-19 patient and literature review: Simple actions for complex times. Medicine. 2021; 100 (23).
  4. Coath F. L., Mackay J., Gaffney J. K. Axial presentation of reactive arthritis secondary to COVID-19 infection. Rheumatology. 2021; 60 (7): e232–e233.
  5. Favalli E. G. Understanding the role of interleukin-6 (IL-6) in the joint and beyond: a comprehensive review of IL-6 inhibition for the management of rheumatoid arthritis. Rheumatology and therapy. 2020; 7 (3): 473–516.
  6. Fusco M. et al. Degenerative joint diseases and neuroinflammation. Pain Practice. 2017; 17 (4): 522–532.
  7. Gasparotto M. et al. Post-COVID-19 arthritis: a case report and literature review. Clinical rheumatology. 2021; 40: 3357–3362.
  8. Gaston J. S. H., Lillicrap M. S. Arthritis associated with enteric infection. Best practice & research Clinical rheumatology. 2003; 17 (2): 219–239.
  9. Heinrich P. C. et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochemical journal. 2003; 374 (1): 1–20.
  10. Hwa K.Y., Lin W. M., Hou Y.I. et al. Peptide mimicrying between SARS coronavirus spike protein and human proteins reacts with SARS patient serum. Journal of Biomedicine and Biotechnology. 2008; 2008.
  11. Lindner D. et al. Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases. JAMA cardiology. 2020; 5 (11): 1281–1285. doi:10.1001/ jamacardio.2020.3551.
  12. McInnes I. B., Buckley C. D., Isaacs J. D. Cytokines in rheumatoid arthritis—shaping the immunological landscape. Nature Reviews Rheumatology. 2016; 12 (1): 63–68.
  13. Selmi C., Gershwin M. E. Diagnosis and classification of reactive arthritis. Autoimmunity reviews. 2014; 13 (4-5): 546–549.
  14. Sun X. et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine & growth factor reviews. 2020; 53: 38–42.
  15. Sureja N. P., Nandamuri D. Reactive arthritis after SARS-CoV-2 infection. Rheumatology advances in practice. 2021; 5 (1): rkab001. doi: 10.1093/rap/rkab001
  16. Peshekhonova L., Peshekhonov D., Krasyukov P. The clinical efficiency of using Osteomed, Osteomed forte, and Osteo-Vit D3 in patients with secondary osteoporosis in rheumatoid arthritis. Vrach. 2020; 31 (4): 68–74. DOI:10.29296/258773052020-04-12
  17. Raskachkin V., Tokarev A., Panov I. The biologically active agent Osteomed in the combination treatment of large joint arthrosis. Vrach. 2018; 29 (1): 63–66. DOI:10.29296/25877305-2018-01-19
  18. Strukov V.I., Sergeeva-Kondrachenko M.Yu., Vinogradova O.P. et al. Relationship between osteoporosis and joint pathologies. New approach to treatment of arthritis and osteoarthritis. Medical alphabet. 2023; (34): 57–62. (In Russ.). DOI:10.33667/2078-5631-2023-34-57-62
  19. Strukov V., Elistratov D., Vikhrev D. et al. A personalized approach to therapy for comorbid osteoporosis in clinical practice. Vrach. 2022; 33 (6): 20–25 (in Russ.). DOI: 10.29296/25877305-2022-06-03
  20. Yarikov A., Denisov A., Masevnin S. et al. Osteoporosis in the practice of a vertebrologist. Vrach. 2020; 31 (3): 11–18 (in Russ.). DOI: 10.29296/25877305-2020-03-02
  21. Strukov V.I., Sergeeva-Kondrachenko M.Yu., Marchenkova L.A., et al. Immunotherapy of postmenopausal osteoporosis and other diseases of the musculoskeletal system against the background of hormonal deficiency. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie. 2022; 2 (10): 14–22 (in Russ.). DOI: 10.33029/2303-9698-2022-10-2-47-55
  22. Marchenkova L.A., Makarova E.V. Possibilities for correction of conditioning and motor coordination problems in osteosarcopenia, by using dietary supplements with calcium and vitamins D3 and B6. Vrach. 2020; 31 (7): 61–68 (in Russ.). DOI: 10.29296/25877305-2020-07-12.